FDA Opens Early Access to Novel Pancreatic Cancer Drug Generating Buzz

The FDA has issued a 'safe to proceed' letter to Revolution Medicines, authorizing an expanded access program (EAP) for the investigational pancreatic cancer drug daraxonrasib. Expanded access programs allow patients with serious or life-threatening conditions to receive experimental treatments outside of clinical trials when no comparable alternatives exist. Pancreatic cancer remains one of the deadliest malignancies with a five-year survival rate below 12%, making any new therapeutic option highly anticipated. The FDA's decision signals confidence in the drug's safety profile and reflects the urgency of unmet need in this patient population.